RxDoctor Payments Data

Patrick Livingston, DO

Family Medicine · Norman, OKNPI 1881687200

Payments from drug & device makers

$612in general payments, 2019–2025

Across 22 payments — averaging $27.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$162
  • Novo Nordisk$130
  • AbbVie$106
  • GSK$87
  • Astellas Pharma US Inc$43
  • Nevro Corp.$22
  • plus $63 from 4 others

What the payments were for

  • Food & beverage$612100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$612 in reported general payments places this provider in the 55th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$177,432
Medicare patients
565
Services billed
2,450

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide53$60,646
EliquisApixaban49$36,242
MyrbetriqMirabegron23$17,791
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$17,340
MounjaroTirzepatide18$14,969
TrulicityDulaglutide11$10,175
FarxigaDapagliflozin Propanediol13$9,519
Advair DiskusFluticasone Propion/Salmeterol17$5,293
Atorvastatin Calcium350$4,936
Omeprazole195$4,126
Levothyroxine Sodium403$3,817
Rosuvastatin Calcium175$3,668
Albuterol Sulfate HfaAlbuterol Sulfate106$3,573
SymbicortBudesonide/Formoterol Fumarate11$2,916
Gabapentin125$2,890

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$130$60,64653 claims
PfizerEliquis$16$36,24249 claims
Lilly USA, LLCMounjaro, Trulicity$14$25,14329 claims
Astellas Pharma US IncMyrbetriq$43$17,79123 claims
GSKTrelegy Ellipta$87$17,34021 claims
AstraZenecaFarxiga, Symbicort$162$12,43524 claims
AbbVieSynthroid$106$1,57123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Norman

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →